Welcome to our dedicated page for TEVA PHARMACEUTICAL INDUSTRIES SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TEVA PHARMACEUTICAL INDUSTRIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TEVA PHARMACEUTICAL INDUSTRIES's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries Limited reported another profitable quarter with net revenues of $3,982 million for the three months ended March 31, 2026, up slightly from $3,891 million a year earlier, as stronger gross profit more than offset higher selling and marketing costs.
Net income attributable to Teva rose to $369 million from $214 million, and diluted earnings per share increased to $0.31 from $0.18. Operating income improved to $652 million, helped by much lower intangible asset impairments compared with the prior year.
Cash and cash equivalents increased to $3,741 million while net cash used in operating activities was $40 million, influenced by a $617 million net use of cash in working capital. Total assets were $40,040 million and total equity rose to $8,232 million.
Teva continued to adjust its portfolio and capital structure. Senior notes and loans decreased to $14,015 million, and assets held for sale of $1,794 million mainly related to the API business remain classified for divestiture. Legal provisions for settlements and loss contingencies totaled $4,680 million, with $72 million of related expenses recorded this quarter.
Strategic R&D and funding transactions advanced the pipeline. Teva agreed to acquire Emalex Biosciences for $700 million plus up to $200 million in milestones, and entered funding agreements with Blackstone Life Sciences and Royalty Pharma that could provide up to $900 million across key late-stage programs. Several collaboration partners, including Sanofi, Alvotech, MedinCell and others, progressed Phase 3 or registration-stage assets, supporting Teva’s Pivot to Growth strategy.
Teva Pharmaceutical Industries reported first quarter 2026 revenues of $3.98 billion, up 2% in U.S. dollars but down 3% in local currencies, as strong growth in key innovative brands offset weaker generics, especially lower U.S. sales of lenalidomide capsules.
GAAP diluted EPS rose to $0.31 from $0.18, while non-GAAP diluted EPS edged up to $0.53 from $0.52, supported by higher gross profit and lower intangible impairments. Innovative products AUSTEDO, AJOVY and UZEDY generated $838 million collectively and grew 41% year over year in local currency.
Teva maintained its 2026 outlook, guiding to revenues of $16.4–$16.8 billion, non-GAAP operating income of $3.8–$4.0 billion and free cash flow of $2.0–$2.4 billion, including the impact of its agreement to acquire Emalex Biosciences for $700 million upfront plus up to $200 million in milestones and royalties tied to ecopipam for pediatric Tourette syndrome.
Teva Pharmaceutical Industries Ltd. is asking shareholders to reappoint Dr. Sol J. Barer as director through 2029, approve executive pay on an advisory basis, and ratify Kesselman & Kesselman (PwC network) as auditor through the 2027 meeting. The Board highlights progress on its “Pivot to Growth” strategy, emphasizing double‑digit growth for key innovative drugs AUSTEDO, UZEDY (including an FDA indication expansion for Bipolar I disorder) and AJOVY, as well as advancement of late‑stage assets like olanzapine LAI and duvakitug, which generated a $500 million Phase 3 milestone payment recorded as 2025 revenue. Teva reports 2025 global revenue growth in local currency, continued net debt reduction, and a stronger balance sheet supported by sustainable finance, including about $7.5 billion of sustainability‑linked bonds and a $1.8 billion sustainability‑linked revolving credit facility. The proxy details Board composition, committee structure, AI and cybersecurity oversight, human capital initiatives for Teva’s 33,950 employees, and an executive compensation framework heavily weighted to variable, performance‑based pay, alongside strengthened stock‑ownership guidelines and no hedging or repricing of underwater options.
Teva Pharmaceutical Industries officer Mark Sabag reported an open-market sale of 62,102 Ordinary Shares on March 17, 2026. The shares were sold at a weighted average price of $30.141 per share, in multiple trades between $30.115 and $30.215.
Following this transaction, Sabag directly owns 224,940 Ordinary Shares. The filing notes that each Ordinary Share may be represented by an American Depositary Share, with each ADS currently corresponding to one Ordinary Share.
Teva Pharmaceutical Industries reported a Form 144 notification for the proposed sale of 62,102 ordinary shares, listed for sale through Citigroup Global Markets Inc. on the NYSE. The shares are identified as rollover/compensation ordinary shares with trade dates listed in March 2026.
Teva Pharmaceutical Industries officer Mark Sabag reported the vesting and settlement of 15,723 restricted share units on March 5, 2026. These units were converted at $0.00 per share into 15,723 ordinary shares, increasing his direct holdings to 287,042 ordinary shares.
Following the transaction, he also held 47,170 restricted share units. The RSUs were originally granted on March 5, 2025, with additional tranches of 15,723 vesting on March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. Each RSU represents a right to one ordinary share or its cash value.
Teva Pharmaceutical Industries EVP and CFO Eliyahu Sharon Kalif acquired shares through vested equity awards. On March 5, 2026, he exercised 19,916 Restricted Share Units at $0.00 per unit, converting them into 19,916 Ordinary Shares.
Following the transactions, his reported direct holdings were 59,748 Restricted Share Units and 325,435 Ordinary Shares. The RSUs stem from a March 5, 2025 grant, with additional tranches of 19,916 units scheduled to vest on March 5 of 2027, 2028, and 2029.
Teva Pharmaceutical Industries Chief Accounting Officer Amir Weiss reported equity compensation activity involving restricted share units. On March 5, 2026, 3,537 restricted share units were converted into 3,537 ordinary shares at no cash exercise price as part of a previously granted award.
The footnotes explain this grant was made on March 5, 2025, with 3,537 units vesting on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029. After this transaction, Weiss directly held 30,695 ordinary shares and 10,613 restricted share units.
Teva Pharmaceutical Industries President and CEO Richard Francis reported vesting and related transactions in company equity on March 5, 2026. He exercised 42,452 Restricted Share Units (RSUs), which converted into the same number of ordinary shares at a stated price of $0.00 per share.
Following the RSU conversion, he held 1,190,664 ordinary shares before selling 20,025 ordinary shares in open-market transactions at a weighted average price of $31.6684 per share to cover tax withholding obligations. After these sales, he directly owns 1,170,639 ordinary shares and 127,359 RSUs, each RSU representing a contingent right to one ordinary share or its cash value. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Ordinary shares may be represented by American Depositary Shares on a one-for-one basis.